Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program
Year: 2009
Type: article
Abstract: Vorinostat, a histone deacetylase inhibitor, was evaluated against the in vitro and in vivo childhood solid tumor and leukemia models in the Pediatric Preclinical Testing Program (PPTP). In vitro testing was performed by the DIMSCAN cytotoxicity assay. In vivo, vorinostat was administered intraperitoneally to mice bearing xenografts. Vorinostat demonstrated 2-log cell growth inhibitory activity in vitro, but generally at concentrations not sustainable in the clinic. No objective responses were observed for any of the solid tumor or acute lymphoblastic leukemia xenografts. Preclinical studies with appropriate drug combinations may provide direction for further clinical evaluations of vorinostat against selected pediatric cancers.
Source: Pediatric Blood & Cancer
DOI: 10.1002/pbc.21988
Institutions: Children's Hospital Los Angeles, St. Jude Children's Research Hospital, Children's Cancer Institute Australia, Duke Medical Center, Children's Hospital of Philadelphia, University of Pennsylvania, Texas Tech University, Texas Tech University Health Sciences Center, Children's Hospital at Montefiore, Alfred I. duPont Hospital for Children, National Cancer Institute
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W1995364339